AXL kinase as a novel target for cancer therapy

被引：153

作者：

Wu, Xiaoliang ^{[1
]}

Liu, Xuewen ^{[1
,2
]}

Koul, Sanjay ^{[2
]}

Lee, Chang Youl ^{[3
]}

Zhang, Zhenfeng ^{[1
]}

Halmos, Balazs ^{[2
]}

机构：

[1] Sun Yat Sen Univ, Ctr Canc, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Guangzhou 510275, Guangdong, Peoples R China

[2] Columbia Univ, New York Presbyterian Hosp, Herbert Irving Comprehens Canc Ctr, Div Hematol Oncol,Med Ctr, New York, NY USA

[3] Hallym Univ, Chuncheon Sacred Heart Hosp, Med Ctr, Div Pulm Allergy & Crit Care Med,Dept Internal Me, Chuncheon Si 200704, Gangwon Do, South Korea

来源：

ONCOTARGET | 2014年 / 5卷 / 20期

基金：

奥地利科学基金会;

关键词：

AXL; receptor tyrosine kinase; lung cancer; targeted therapy; CHRONIC MYELOID-LEUKEMIA; STAT5A SERINE PHOSPHORYLATION; GTPASE-ACTIVATING PROTEIN; TYROSINE KINASE; STEM-CELLS; DNA-BINDING; MAMMARY-GLAND; RAC GTPASES; IN-VITRO; INHIBITOR;

D O I：

10.18632/oncotarget.2542

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The AXL receptor tyrosine kinase and its major ligand, GAS6 have been demonstrated to be overexpressed and activated in many human cancers (such as lung, breast, and pancreatic cancer) and have been correlated with poor prognosis, promotion of increased invasiveness/metastasis, the EMT phenotype and drug resistance. Targeting AXL in different model systems with specific small molecule kinase inhibitors or antibodies alone or in combination with other drugs can lead to inactivation of AXL-mediated signaling pathways and can lead to regained drug sensitivity and improved therapeutic efficacy, defining AXL as a promising novel target for cancer therapeutics. This review highlights the data supporting AXL as a novel treatment candidate in a variety of cancers as well as the current status of drug development targeting the AXL/GAS6 axis and future perspectives in this emerging field.

引用

页码：9546 / 9576

页数：31

共 106 条

[1] Critical Role of Jak2 in the Maintenance and Function of Adult Hematopoietic Stem Cells [J].

Akada, Hajime ;

Akada, Saeko ;

Hutchison, Robert E. ;

Sakamoto, Kazuhito ;

Wagner, Kay-Uwe ;

Mohi, Golam .

STEM CELLS, 2014, 32 (07) :1878-1889

[2] RETRACTED: A cytosolic protein-tyrosine phosphatase PTP1B specifically dephosphorylates and deactivates prolactin-activated STAT5a and STAT5b (Retracted Article) [J].

Aoki, N ;

Matsuda, T .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (50) :39718-39726

[3]

Baines AT, 2011, FUTURE MED CHEM, V3, P1787, DOI [10.4155/FMC.11.121, 10.4155/fmc.11.121]

[4] CDK8 Kinase Phosphorylates Transcription Factor STAT1 to Selectively Regulate the Interferon Response [J].

Bancerek, Joanna ;

Poss, Zachary C. ;

Steinparzer, Iris ;

Sedlyarov, Vitaly ;

Pfaffenwimmer, Thaddaeus ;

Mikulic, Ivana ;

Doelken, Lars ;

Strobl, Birgit ;

Mueller, Mathias ;

Taatjes, Dylan J. ;

Kovarik, Pavel .

IMMUNITY, 2013, 38 (02) :250-262

[5]

Bandapalli OR, 2014, HAEMATOLOGICA

[6]

Berger A, 2013, LEUKEMIA

[7] Stat5a serine phosphorylation -: Serine 779 is constitutively phosphorylated in the mammary gland, and serine 725 phosphorylation influences prolactin-stimulated in vitro DNA binding activity [J].

Beuvink, I ;

Hess, D ;

Flotow, H ;

Hofsteenge, J ;

Groner, B ;

Hynes, NE .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (14) :10247-10255

[8] Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy [J].

Bibi, Siham ;

Arslanhan, Melis Dilara ;

Langenfeld, Florent ;

Jeanningros, Sylvie ;

Cerny-Reiterer, Sabine ;

Hadzijusufovic, Emir ;

Tchertanov, Luba ;

Moriggl, Richard ;

Valent, Peter ;

Arock, Michel .

HAEMATOLOGICA, 2014, 99 (03) :417-429

[9] Phase I trial of the combination of flavopiridol and imatinib mesylate in patients with Bcr-Abl+ hematological malignancies [J].

Bose, Prithviraj ;

Perkins, Edward B. ;

Honeycut, Connie ;

Wellons, Martha D. ;

Stefan, Tammy ;

Jacobberger, James W. ;

Kontopodis, Emmanouil ;

Beumer, Jan H. ;

Egorin, Merrill J. ;

Imamura, Chiyo K. ;

Figg, W. Douglas, Sr. ;

Karp, Judith E. ;

Koc, Omer N. ;

Cooper, Brenda W. ;

Luger, Selina M. ;

Colevas, A. Dimitrios ;

Roberts, John D. ;

Grant, Steven .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 69 (06) :1657-1667

[10] Mechanism of Activation of Protein Kinase JAK2 by the Growth Hormone Receptor [J].

Brooks, Andrew J. ;

Dai, Wei ;

O'Mara, Megan L. ;

Abankwa, Daniel ;

Chhabra, Yash ;

Pelekanos, Rebecca A. ;

Gardon, Olivier ;

Tunny, Kathryn A. ;

Blucher, Kristopher M. ;

Morton, Craig J. ;

Parker, Michael W. ;

Sierecki, Emma ;

Gambin, Yann ;

Gomez, Guillermo A. ;

Alexandrov, Kirill ;

Wilson, Ian A. ;

Doxastakis, Manolis ;

Mark, Alan E. ;

Waters, Michael J. .

SCIENCE, 2014, 344 (6185) :710-+

← 1 2 3 4 5 6 7 8 9 10 →